Wall Street analysts predict that Myovant Sciences Ltd (NYSE:MYOV) will announce earnings of ($0.47) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Myovant Sciences’ earnings. Myovant Sciences posted earnings per share of ($0.39) during the same quarter last year, which would indicate a negative year-over-year growth rate of 20.5%. The company is scheduled to issue its next earnings results on Thursday, August 9th.
On average, analysts expect that Myovant Sciences will report full year earnings of ($1.58) per share for the current year, with EPS estimates ranging from ($1.95) to ($1.20). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that cover Myovant Sciences.
Myovant Sciences (NYSE:MYOV) last announced its quarterly earnings results on Tuesday, June 12th. The company reported ($0.81) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by ($0.04).
In other news, Director Mark Altmeyer bought 3,500 shares of the company’s stock in a transaction on Saturday, November 17th. The shares were bought at an average cost of $13.38 per share, with a total value of $46,830.00. Following the transaction, the director now directly owns 3,500 shares in the company, valued at approximately $46,830. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Holdings Ltd. Dexxon bought 1,110,015 shares of the company’s stock in a transaction on Monday, April 2nd. The stock was purchased at an average cost of $20.27 per share, for a total transaction of $22,500,004.05. The disclosure for this purchase can be found here. Corporate insiders own 3.00% of the company’s stock.
A number of hedge funds have recently modified their holdings of MYOV. Swiss National Bank boosted its stake in shares of Myovant Sciences by 12.7% during the 1st quarter. Swiss National Bank now owns 28,300 shares of the company’s stock worth $602,000 after acquiring an additional 3,200 shares in the last quarter. Platinum Investment Management Ltd. bought a new stake in Myovant Sciences during the 1st quarter valued at approximately $1,152,000. Ardsley Advisory Partners bought a new stake in Myovant Sciences during the 4th quarter valued at approximately $1,272,000. Millennium Management LLC boosted its stake in Myovant Sciences by 54.3% during the 1st quarter. Millennium Management LLC now owns 106,868 shares of the company’s stock valued at $2,273,000 after purchasing an additional 37,602 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in Myovant Sciences by 6.2% during the 1st quarter. JPMorgan Chase & Co. now owns 106,944 shares of the company’s stock valued at $2,275,000 after purchasing an additional 6,263 shares during the period. 18.46% of the stock is currently owned by institutional investors.
Myovant Sciences traded down $0.11, reaching $22.58, during trading hours on Friday, Marketbeat.com reports. The company’s stock had a trading volume of 2,334 shares, compared to its average volume of 48,982. The company has a quick ratio of 3.09, a current ratio of 3.09 and a debt-to-equity ratio of 1.16. The stock has a market cap of $1.47 billion, a PE ratio of -9.37 and a beta of -2.15. Myovant Sciences has a 1 year low of $9.92 and a 1 year high of $24.91.
Myovant Sciences Company Profile
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.